摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- | 112434-52-3

中文名称
2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基-
中文别名
——
英文名称
7-amino-5-(4-methoxyphenyl)-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
英文别名
7-amino-5-(4-methoxyphenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile;7-amino-5-(4-methoxyphenyl)-2,4-dioxo-1,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile
2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基-化学式
CAS
112434-52-3
化学式
C15H12N4O4
mdl
——
分子量
312.285
InChiKey
RJFJKSJXBIQQFI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    287-288 °C
  • 密度:
    1.52±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    23
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    127
  • 氢给体数:
    3
  • 氢受体数:
    6

SDS

SDS:2a2efa90e250f648eeabaac826240e52
查看

反应信息

  • 作为反应物:
    描述:
    2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基-正丁醇 为溶剂, 反应 11.0h, 生成 6-imino-5-(4-methoxyphenyl)-2,4-dioxo-N-phenyl-1,3,4,5-tetrahydro-2H-pyrano[2,3-d:6,5-d’]dipyrimidine-7(6H)-carbothioamide
    参考文献:
    名称:
    吡喃并[2,3-d]嘧啶衍生物作为抗菌剂和抗癌剂的设计、合成、分子对接和计算机模拟ADMET谱
    摘要:
    通过在丁醇中用醛和丙二腈处理含有活性亚甲基的环状化合物合成吡喃并[2,3- d ]嘧啶衍生物。吡喃并[2,3- d ]嘧啶对一些亲电体的行为,即原甲酸三乙酯,然后是氮亲核体,如异丁胺、尿素、苯基硫脲、对甲苯胺、邻苯二胺、邻氨基苯酚、2-氨基-4-甲基-吡啶和乙酸的目的是获得一些有趣的非混合杂环化合物。所有合成的化合物在某种程度上都对通过抑制细胞壁合成而提取的不同微生物菌株显示出良好的抗菌活性。化合物5b对枯草芽孢杆菌的抗菌活性最高、金黄色葡萄球菌和大肠杆菌。另一方面,化合物5 g分别对铜绿假单胞菌和黑曲霉表现出最高的抗菌和抗真菌活性。此外,他们通过DNA 嵌入和 Top-II 抑制探索了对不同细胞系的细胞毒性潜力。细胞毒活性表明衍生物5a对HepG2细胞有很强的抑制活性,IC 50  = 2.09 μM,而HCT-116细胞对衍生物5c高度敏感,IC 50  = 2.61 μM,同时衍生物5f 与其他制备的化合物相比,对
    DOI:
    10.1016/j.bioorg.2021.105186
  • 作为产物:
    描述:
    4-甲氧基苯甲醛 在 C22H18N6O5V(1-)*Cs(1+) 作用下, 以 乙醇 为溶剂, 反应 1.5h, 生成 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基-
    参考文献:
    名称:
    多核[VIVO]/[VVO2]配合物中基于三氨基胍的μ3配体的受控修饰及其在2-氨基-3-氰基-4H-吡喃/4H-色烯合成中的催化潜力
    摘要:
    三(2-羟基亚苄基)-三氨基胍氯化物 ( I ·HCl) 和三(5-溴-2-羟基亚苄基)-三氨基胍氯化物 ( II ·HCl) 与 [V IV O(acac) 2 ] (1:1 摩尔)的反应比例)在回流甲醇中产生单核 [V IV O] 配合物,[V IV O(H 2 L 1' )(MeOH)] ( 1 ) 和 [V IV O(H 2 L 2' )(MeOH)] ( 2 ),分别,其中I和II经历分子内三唑环形成。在 Cs 2 CO 3存在下,在 MeOH 中空气氧化1和2,得到相应的顺式-[V V O 2 ] 配合物 Cs[(VO 2 )(H 2 L 1' )] ( 3 ) 和 Cs[(VO 2 ) )(H 2 L 2′ )]( 4 )。然而,空气氧化的 [V IV O(acac) 2 ] 甲醇溶液与I ·HCl 和II ·HCl 在 Cs 2 CO 3存在下(摩尔比为 1:1:1)反应,得到单核配合物
    DOI:
    10.1021/acs.inorgchem.3c03704
点击查看最新优质反应信息

文献信息

  • Synthesis of functionalized chromene and spirochromenes using l -proline-melamine as highly efficient and recyclable homogeneous catalyst at room temperature
    作者:Sakkani Nagaraju、Banoth Paplal、Kota Sathish、Santanab Giri、Dhurke Kashinath
    DOI:10.1016/j.tetlet.2017.09.060
    日期:2017.11
    commercially cheap l-proline and melamine for the synthesis of chromenes and spirochromenes (spirooxindoles) via multicomponent reactions at room temperature. Systematic studies were conducted in order to achieve desired reactivity and recyclability of the catalyst using various α-amino acids and aromatic amines as donor-acceptor pairs. Among the screened combinations, l-proline and melamine (3:1 ratio;
    使用便宜的1-脯酸和三聚氰胺开发了一种有效且可循环使用的均相催化剂,用于在室温下通过多组分反应合成色烯和螺环色酮(螺并辛多烯)。为了使用各种α-氨基酸和芳族胺作为供体-受体对,进行系统研究以实现所需的反应性和催化剂的可回收性。在筛选的组合中,l脯酸和三聚氰胺(3:1的比例;占总重量的3 mol%)被认为是最佳的催化剂,可以在室温下非常短的时间内(1-15分钟)以优异的产率(高达99%)提供所需的产品在DMSO中作为溶剂。通过添加EtOAc来回收催化剂,并且在不损失催化活性的情况下重复使用多达5个循环。
  • Verjuice as a green and bio-degradable solvent/catalyst for facile and eco-friendly synthesis of 5-arylmethylenepyrimidine-2,4,6-trione, pyrano[2,3-d]pyrimidinone and pyrimido[4,5-d]pyrimidinone derivatives
    作者:Niloufar Safari、Farhad Shirini、Hassan Tajik
    DOI:10.1007/s13738-018-1565-y
    日期:2019.4
    of the synthesis of 5-arylmethylenepyrimidine-2,4,6-triones, via Knovenagel condensation reaction between barbituric or thiobarbituric acid and aldehydes. Verjuice is also employed for the effective synthesis of pyrano[2,3-d]pyrimidinone derivatives via a three-component reaction of barbituric acid or its thio analogue, aldehydes and malononitrile. In the same way, pyrimido[4,5-d]pyrimidinone derivatives
    Verjuice(未成熟的葡萄汁)是一种有机酸的天然混合物,可通过pH值和TGA分析鉴定,可通过Knovenagel缩合有效地用于促进5-芳基亚甲基嘧啶-2,4,6-三酮的合成。巴比妥酸巴比妥酸与醛之间的反应。Verjuice还用于通过巴比妥酸或其代类似物,醛和丙二腈的三组分反应有效合成喃并[2,3- d ]嘧啶酮衍生物。同样,嘧啶基[4,5- d]嘧啶酮衍生物可简单地通过巴比妥酸,醛与硫脲在果汁中的反应来制备。这种绿色方法学具有显着的优势,包括操作简单,可接受的反应时间,易于后处理,高收率,避免在反应和后处理过程中使用任何昂贵的起始原料,挥发性和有害有机溶剂以及使用天然,低成本,可重复使用且可生物降解的催化剂。
  • DABCO-based ionic liquids: green and recyclable catalysts for the synthesis of barbituric and thiobarbituric acid derivatives in aqueous media
    作者:Narges Seyyedi、Farhad Shirini、Mohaddeseh Safarpoor Nikoo Langarudi
    DOI:10.1039/c6ra05878g
    日期:——
    the reaction of barbituric or thiobarbituric acid, malononitrile and aldehydes in the presence of this reagent and 1,4-disulfo-1,4-diazabicyclo[2.2.2]octane-1,4-diium chloride ([DABCO](SO3H)2(Cl)2) has been investigated. The structure of the products was characterized using IR, 1H NMR and 13C NMR spectroscopy. The present methodologies suggests several advantages such as ease of the preparation and
    一种新的,直接的方法,可通过使用1,4-二磺基-1,4-二氮杂双环[2.2.2]辛烷-1通过巴比妥酸及其代类似物与醛的反应来合成5-芳基巴比妥酸巴比妥酸,已经报道了作为有效催化剂的4-二硫酸氢二([DABCO](SO 3 H)2(HSO 4)2)。在该项目中,还通过在该试剂和1,4-二磺基-1,4-二氮杂双环[2.2]存在下,通过巴比妥酸巴比妥酸丙二腈和醛的反应制备喃并[2,3- d ]-嘧啶二酮。 .2]辛烷-1,4-氯化铵([DABCO](SO 3 H)2(Cl)2)已被调查。使用IR,1 H NMR和13 C NMR光谱对产物的结构进行表征。本方法论提出了若干优点,例如易于制备和处理催化剂,高收率,简单和绿色的方法,低成本,短的反应时间,易于后处理和在中作为绿色溶剂进行反应的预形成。
  • Introduction of an efficient DABCO-based bis-dicationic ionic salt catalyst for the synthesis of arylidenemalononitrile, pyran and polyhydroquinoline derivatives
    作者:Mehdi Zabihzadeh、Atefeh Omidi、Farhad Shirini、Hassan Tajik、Mohaddeseh Safarpoor Nikoo Langarudi
    DOI:10.1016/j.molstruc.2020.127730
    日期:2020.4
    Abstract —An affordable DABCO-based bis-dicationic ionic salt ([(DABCO)2C3H5OH]·2Cl) was utilized for the synthesis of arylidenemalononitrile, tetrahydrobenzo[b]pyran, pyrano[2,3-d]-pyrimidinone (thione), dihydropyrano[3,2-c]chromene, and polyhydroquinoline derivatives. The significant features of the presented method are ease of preparation and handling of the catalyst, high catalytic activity, short
    摘要 —一种经济实惠的基于 DABCO 的双阳离子离子盐 ([(DABCO)2C3H5OH]·2Cl) 用于合成亚芳基丙二腈、四氢苯并[b]喃、喃并[2,3-d]-嘧啶酮(酮),二氢喃并[3,2-c]色烯和聚氢喹啉生物。该方法的显着特点是催化剂易于制备和处理,催化活性高,反应时间短,无需柱色谱分离,后处理程序简单。此外,催化剂可以很容易地回收并在研究的反应中重复使用几个循环。
  • Succinimidinium N-sulfonic acid hydrogen sulfate as an efficient ionic liquid catalyst for the synthesis of 5-arylmethylene-pyrimidine-2,4,6-trione and pyrano[2,3-d]pyrimidinone derivatives
    作者:Masoumeh Abedini、Farhad Shirini、Javad Mohammad-Alinejad Omran、Mohadeseh Seddighi、Omid Goli-Jolodar
    DOI:10.1007/s11164-015-2289-6
    日期:2016.5
    ([SuSA-H]HSO4) as a new ionic liquid is prepared and characterized using a variety of techniques, including infrared spectra (FT-IR), 1H and 13C NMR, scanning electron microscopy, a mass spectra method, as well as by Hammett acidity function. The prepared reagent is efficiently able to catalyze the preparation of 5-arylmethylene-pyrimidine-2,4,6-triones via the condensation of aldehydes and barbituric acid
    使用多种技术制备并表征了琥珀酰亚胺 N- 磺酸硫酸氢盐([SuSA-H] HSO 4),并使用多种技术进行了表征,包括红外光谱(FT-IR),1 H和13 C NMR,扫描电子显微镜,质谱方法以及Hammett酸度函数。通过醛和巴比妥酸的缩合,所制备的试剂能够有效地催化5-芳基亚甲基-嘧啶-2,4,6-三酮的制备。进一步的研究表明,醛与巴比妥酸丙二腈的缩合反应生成喃并[2,3- d 在该试剂的存在下,也可以有效地促进]嘧啶酮衍生物。本发明的方法具有几个优点,包括易于制备和处理催化剂,简单和容易的后处理,短的反应时间,产物的高产率和催化剂的可回收性。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione